Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 71610-707

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71610-707). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 500 mg (71610 0707 53)

Bottle Label 500 mg (71610 0707 53)
Divalproex Sodium ER 500 mg extended-release tablets, film-coated, oral dosage form. The carton contains 60 tablets and is labeled with NDC 71610-0707-53. The labeler is Aphena Pharma Solutions - Tennessee, LLC, with packaging by Patheon of Thermo Fisher Scientific in Puerto Rico. Storage instructions specify 20-25 degrees Celsius.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Divalproex Structural Formula (Image 03)

Divalproex Structural Formula (Image 03)
Chemical structure of divalproex sodium, showing the polymeric form consisting of valproate units coordinated with sodium ions.*
FDA Label Image

Figure 1: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Adjunctive Therapy Study (Image 04)

Figure 1: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Adjunctive Therapy Study (Image 04)
A cumulative distribution plot showing the percentage reduction in CPS rate for patients treated with Divalproex Sodium Delayed-Release compared to placebo. The x-axis represents percent of patients and the y-axis shows percent reduction in CPS rate, with improvement above zero and worsening below zero. The solid line represents Divalproex Sodium Delayed-Release and the dashed line represents placebo.*
FDA Label Image

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)
A line chart comparing the percentage reduction in CPS rate for patients taking high dose versus low dose Divalproex Sodium delayed release. The x-axis shows the percentage of patients from 100% to 0%, and the y-axis shows percent reduction in CPS rate from -100% to 100%, with indicators for 'Improvement' above and 'Worsening' below a 'No Change' baseline.*
FDA Label Image

Figure 3. Mean Reduction In 4-week Migraine Headache Rates (Image 06)

Figure 3. Mean Reduction In 4-week Migraine Headache Rates (Image 06)
A bar graph comparing placebo and Divalproex Sodium Extended-Release Tablets. The y-axis represents a measured variable with values from 0 to 1.2. The placebo bar is approximately 0.6, while the Divalproex Sodium bar reaches about 1.2, marked with an asterisk indicating statistical significance (p=0.006).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.